ADVANCING IMMUNO-ONCOLOGY
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
CLINICAL TRIALS
IOVANCE is conducting five Phase 2 clinical trials to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes for treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer.
C-144-01 is a multicenter clinical trial for patients with Metastatic Melanoma at various sites in the US and Europe.
C-145-03 is a multicenter clinical trial now recruiting patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at various sites in the US.
IOV-LUN-201 is a multicenter clinical trial now recruiting patients with Non-Small Cell Lung Cancer (NSCLC) at various sites in the US.
C-145-04 is a multicenter clinical trial now recruiting patients with Cervical Carcinoma at various sites in the US and Europe.
IOV-COM-202 is a multicenter clinical trial now recruiting patients with Solid Tumors at various sites in the US.
Learn